ObvioHealth Appoints CFO, VP of Science

ObvioHealth, a virtual research organization (VRO), has appointed John Cassidy as its new chief financial officer and Florence Mowlem as vice president of Science. The hires are designed to reinforce the company’s clinical and digital trial expertise. 

Cassidy specializes in driving organizational transformations for companies at the intersection of clinical research, healthcare, and technology. He has held leadership roles in finance, sales, and operations; Cassidy’s most recent position was global head of Product and Commercial for eClinical at LabCorp followed his stewardship of that company’s acquisition of snapIoT. Cassidy’s exposure to clinical trial mobile technology predates that of most industry experts—he worked as corporate controller for Parallel 6 before it was acquired by PRA Health Sciences. At ObvioHealth, he works alongside the executive team to develop robust financial infrastructure, controls, and planning.
 
“ObvioHealth has a unique model blending clinical expertise with a robust platform to deliver stronger evidence and accelerated timelines for drug development,” Cassidy said. “It is the perfect time to join this experienced team to help bring the business to a new level of growth.”  
 
Mowlem comes to ObvioHealth from Medable, where she led a team driving the implementation of electronic clinical outcomes assessments (eCOAs). Previously at Signant Health, Mowlem employed her scientific expertise to guide COA digitalization and the use of connected health devices in clinical trials. 
 
Florence earned a Ph.D. in social, genetic and developmental psychiatry from Kings College, and brings a progressive mindset to the scientific practice of digital endpoints capture. She will play a pivotal role at ObvioHealth, working with both clinical and technology teams to optimize the implementation of eCOAs according to industry, regulatory, and scientific best practices. 
 
“I am excited by ObvioHealth’s strategic and innovative approach to advancing the use of health devices in clinical trials to support the needs of all stakeholders,” Mowlem stated. “I hope to help shape the company’s scientific strategy to put ObvioHealth at the forefront of life-improving clinical research practices.” 
 
New York, N.Y.-based ObvioHealth aims to conduct innovative and efficient trials that deliver stronger evidence for better health outcomes. The company uses technology to develop more precise and accessible measurement tools to capture more robust and accurate data—so life-improving innovations can get to market faster.